Graduate Medical Education
Amino Acids, Peptides, and Proteins | Cardiology | Cardiovascular Diseases | Hormones, Hormone Substitutes, and Hormone Antagonists | Pathological Conditions, Signs and Symptoms
AIMS: The arginine vasopressin (AVP) pathway has been extensively studied in heart failure (HF) with reduced ejection fraction (HFrEF), but less is known about AVP in HF with preserved EF (HFpEF). Furthermore, the association between AVP and atrial natriuretic peptide (ANP, a well-known inhibitor of AVP secretion) in HF is unknown.
METHODS AND RESULTS: We studied subjects with HFpEF (n = 28) and HFrEF (n = 25) and without HF (n = 71). Left ventricular (LV) mass and left atrial (LA) volumes were measured with cardiac magnetic resonance imaging. Arginine vasopressin and ANP were measured with enzyme-linked immunosorbent assay. Arginine vasopressin levels were significantly greater in HFpEF [0.96 pg/mL; 95% confidence interval (CI) = 0.83-1.1 pg/mL] compared with subjects without HF (0.69 pg/mL; 95% CI = 0.6-0.77 pg/mL; P = 0.0002). Heart failure with preserved ejection fraction (but not HFrEF) was a significant predictor of higher AVP after adjustment for potential confounders. Arginine vasopressin levels were independently associated with a greater LA volume and also paradoxically, with lower ANP levels. Key independent correlates of higher AVP were the presence of HFpEF (standardized beta = 0.32; 95% CI = 0.09-0.56; P = 0.0073) and the ANP/LA volume ratio (standardized beta = -0.23; 95% CI = -0.42 to -0.04; P = 0.0196). Arginine vasopressin levels were independently associated with LV mass (beta = 0.26; 95% CI = 0.09-0.43; P = 0.003) and with an increased risk of death or HF admissions during follow-up (hazard ratio = 1.61; 95% CI = 1.13-2.29; P = 0.008).
CONCLUSIONS: Arginine vasopressin is increased in HFpEF and is associated with LV hypertrophy and poor outcomes. Higher AVP is associated with the combination of LA enlargement and paradoxically low ANP levels. These findings may indicate that a relative deficiency of ANP (an inhibitor of AVP secretion) in the setting of chronically increased LA pressure may contribute to AVP excess.
Arginine vasopressin, Atrial natriuretic peptide, Heart failure with preserved ejection fraction, Left atrium, Left ventricular hypertrophy
Rights and Permissions
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
DOI of Published Version
ESC Heart Fail. 2018 Oct;5(5):911-919. doi: 10.1002/ehf2.12319. Epub 2018 Jul 3. Link to article on publisher's site
ESC heart failure
Chirinos, Julio A.; Sardana, Mayank; Oldland, Garrett; Ansari, Bilal; Lee, Jonathan; Hussain, Anila; Mustafa, Anique; Akers, Scott R.; Wei, Wen; Lakatta, Edward G.; and Fedorova, Olga V., "Association of arginine vasopressin with low atrial natriuretic peptide levels, left ventricular remodelling, and outcomes in adults with and without heart failure" (2018). Open Access Articles. 3655.
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License
Amino Acids, Peptides, and Proteins Commons, Cardiology Commons, Cardiovascular Diseases Commons, Hormones, Hormone Substitutes, and Hormone Antagonists Commons, Pathological Conditions, Signs and Symptoms Commons